Bbva Compass Bancshares Inc. bought a new stake in Iqvia Holdings Inc (NYSE:IQV) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 2,627 shares of the medical research company’s stock, valued at approximately $257,000.

A number of other large investors have also bought and sold shares of IQV. Exxonmobil Investment Management Inc. TX purchased a new position in Iqvia in the fourth quarter valued at $2,266,000. DnB Asset Management AS purchased a new position in Iqvia in the fourth quarter valued at $8,813,000. First Citizens Bank & Trust Co. purchased a new position in Iqvia in the fourth quarter valued at $1,067,000. Franklin Street Advisors Inc. NC purchased a new position in Iqvia in the fourth quarter valued at $7,446,000. Finally, Nisa Investment Advisors LLC purchased a new position in Iqvia in the fourth quarter valued at $920,000. 96.09% of the stock is currently owned by hedge funds and other institutional investors.

In other Iqvia news, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $99.97, for a total value of $999,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 30,000 shares of company stock valued at $3,011,800 in the last 90 days. 6.40% of the stock is currently owned by insiders.

Several equities analysts recently commented on the company. Mizuho lowered Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Thursday, November 9th. Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a report on Friday, January 19th. KeyCorp reissued a “sector weight” rating and issued a $100.00 target price on shares of Iqvia in a report on Friday, November 10th. JPMorgan Chase & Co. increased their target price on Iqvia from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, ValuEngine raised Iqvia from a “hold” rating to a “buy” rating in a report on Tuesday, February 20th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and an average target price of $110.02.

Iqvia Holdings Inc (IQV) opened at $98.17 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 1.21. Iqvia Holdings Inc has a 12 month low of $76.51 and a 12 month high of $110.67. The stock has a market cap of $20,420.00, a price-to-earnings ratio of 65.45, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64.

Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.34 by ($0.02). Iqvia had a net margin of 13.44% and a return on equity of 13.03%. The company had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the prior year, the company earned $1.09 EPS. The business’s revenue was up 10.7% on a year-over-year basis. equities research analysts forecast that Iqvia Holdings Inc will post 2.84 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Want to see what other hedge funds are holding IQV? Visit to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with's FREE daily email newsletter.